Calendar: Leadership Development Workshops in Concord, NC


1st – Gracie Wilson

3rd – Jonathan Hinson

4th – Margaret Whittington

9th – Missy Nowlin

11th – Addison Hartz

12th – Brittany Parrish

15th – Colby Stegall

20th – Robert Cassidy

21st – Kristin Coberly, Kevin Furr, Sophia Maciel

25th – Rodney Quesenberry

26th – Ruth Wentz

27th – Vickie Bollinger, Cynthia Mitchell

28th – Tim Tucker

31st – Juanita Clay

“I think, at a child's birth, if a mother could ask a fairy godmother to

endow it with the most useful gift, that gift should be curiosity.”

~Eleanor Roosevelt~

21st – Jim & Elizabeth Pritchett



Recently the United States lost Senator John McCain to glioblastoma, or GBM, which is a type of primary brain cancer, meaning that is has not been caused by cancer in another part of the body. Senator Ted Kennedy died of the same diagnosis on August 25, 2009, the same date as Sen. McCain nine years later.

GBM is more likely to appear in older adults, and more commonly in men than women. Each year in the United States approximately 12, 500 new cases of GBM or brain tumors that may develop into GBM are diagnosed. Like pancreatic cancer, it is one of the less commonly diagnosed cancers but has limited treatment options.

 As the tumor grows, it can cause nonspecific symptoms such as headaches, nausea and vomiting or drowsiness. Other symptoms may include seizures, vision changes, problems with memory or speech, or even weakness on one side of the body. GBM is a fast-growing tumor that can spread quickly.  Surgery is an option but may sometimes not be able to remove the entire tumor. GBM can also reoccur after treatment with chemotherapy and radiation.

A new therapy known as Optune is showing promise for people with recurrent GBM. It is a device worn by the patient which looks similar to the setup for a brain electroencephalogram, or EEG. The device is carried in a purse or backpack and is worn for at least 18 hours daily. When turned on, the device creates low intensity electric fields known as tumor treating fields, or TTF. These TTF fields directly target rapid growing cancer cells to stop their rapid growth or even destroy them. It does not affect normal body cells, which tend to grow more slowly and do not divide as often. The patient’s quality of life is often better with this device as compared to chemotherapy alone, which often makes patients very sick.

 A recent study showed that Optune added to chemotherapy doubled the

5-year GBM survival rate to 13%, compared to 5% for chemotherapy alone. The 2-year survival rate for Optune is 43%, compared to 31% on chemotherapy alone. Patients also reported their mental, emotional, and physical well- being were greatly improved. For more information visit